Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -175.88M | -186.26M | -178.23M | -175.72M | -190.05M |
| Total Depreciation and Amortization | 17.47M | 18.96M | 19.03M | 19.17M | 18.91M |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Non-Cash Items | 43.02M | 46.38M | 31.72M | 26.18M | 26.74M |
| Change in Net Operating Assets | -7.95M | -1.96M | -4.24M | -10.19M | 7.64M |
| Cash from Operations | -123.33M | -122.87M | -131.71M | -140.57M | -136.75M |
| Capital Expenditure | -1.84M | -730.00K | -813.00K | -883.00K | -3.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.42M | 12.95M | 35.57M | 34.98M | 123.67M |
| Cash from Investing | 37.58M | 12.22M | 34.76M | 34.10M | 120.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 75.49M | 75.49M | 75.49M | 75.55M |
| Repurchase of Common Stock | -666.00K | -666.00K | -846.00K | -846.00K | -180.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.07M | 25.07M | 21.94M | 21.94M | 20.00M |
| Cash from Financing | 4.40M | 99.89M | 96.58M | 96.58M | 95.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.35M | -10.76M | -375.00K | -9.89M | 79.25M |